Package Leaflet: Information for the Patient
Teriflunomide Desitin 14 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
What is Teriflunomide Desitin
Teriflunomide contains the active substance teriflunomide, which is an immunomodulatory agent that adjusts the immune system to limit its attack on the nervous system.
What is Teriflunomide Desitin used for
Teriflunomide is used in adults and in children and adolescents (10 years of age and older) to treat relapsing-remitting multiple sclerosis (MS).
What is multiple sclerosis
MS is a long-term disease that affects the central nervous system (CNS). The CNS consists of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (myelin) that surrounds the nerves of the CNS. This loss of myelin is called demyelination. This causes the nerves to stop functioning properly.
People with the relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by the malfunctioning of the nerves. These symptoms vary from patient to patient but usually include:
Symptoms may disappear completely after a relapse, but over time, some problems may persist. This can lead to physical disabilities that can interfere with daily activities.
How Teriflunomide Desitin works
Teriflunomide helps protect against attacks on the central nervous system by the immune system, limiting the growth of certain white blood cells (lymphocytes). This limits the inflammation that causes nerve damage in MS.
Do not take Teriflunomide Desitin:
In case of doubt, ask your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication if:
Respiratory reactions
Inform your doctor if you have cough and shortness of breath without explanation. Your doctor may perform additional tests.
Children and adolescents
Teriflunomide is not indicated for use in children under 10 years of age, as it has not been studied in patients with MS in this age group.
The warnings and precautions listed above also apply to children. The following information is important for children and their caregivers:
Other medications and Teriflunomide Desitin
Inform your doctor or pharmacist if you are taking, have recently taken, or may take any other medication. This includes medications without a prescription.
In particular, inform your doctor or pharmacist if you are taking any of the following medications:
Pregnancy and breastfeeding
Do nottake teriflunomide if you are pregnant or think you may be pregnant. If you are pregnant or become pregnant while taking teriflunomide, the risk of having a baby with birth defects will increase. Women of childbearing age should not take this medication unless they are using reliable contraceptive methods.
If your daughter has her first menstrual period while taking teriflunomide, she should inform her doctor, who will provide specialized advice on contraceptive methods and potential risks in case of pregnancy.
Inform your doctor if you plan to become pregnant after stopping treatment with this medication, as you will need to make sure that most of the medication has been eliminated from your body before trying to become pregnant. The natural elimination of the active substance may take up to 2 years. This period can be reduced to a few weeks by taking certain medications to accelerate the elimination of teriflunomide from the body.
In any case, you need your doctor to confirm, based on a blood test, that the level of the active substance in your blood is low enough for you to become pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect you are pregnant while taking teriflunomide or in the two years following the end of treatment, you should stop taking teriflunomide and contact your doctor immediatelyto have a pregnancy test. If the test confirms pregnancy, your doctor may suggest treatment with certain medications to eliminate teriflunomide from your body quickly, as this may reduce the risk to your baby.
Contraception
You must use an effective contraceptive method during and after treatment with teriflunomide. Teriflunomide remains in the blood for a long time after stopping it. Continue to take contraceptive measures after stopping treatment.
Do not take teriflunomide during breastfeeding, as teriflunomide passes into breast milk.
Driving and using machines
Teriflunomide may cause dizziness, which may affect your ability to concentrate and react. If you are affected, do not drive or use machines.
Teriflunomide Desitin contains lactose and sodium
Teriflunomide contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
A doctor with experience in treating multiple sclerosis will supervise treatment with teriflunomide.
Follow the instructions for administering this medication exactly as indicated by your doctor. In case of doubt, consult your doctor again.
Adults
The recommended dose is one 14 mg tablet per day.
Use in children and adolescents (10 years of age and older)
The dose depends on body weight:
Your doctor will instruct children and adolescents who reach a stable body weight of over 40 kg to switch to a 14 mg tablet per day.
Form/Route of Administration
Teriflunomide is administered orally. Teriflunomide is taken once a day in a single daily dose at any time of day.
The tablet should be swallowed whole with water.
Teriflunomide can be taken with or without food.
If you take more Teriflunomide Desitin than you should
If you have taken too much teriflunomide, call your doctor immediately. You may experience side effects similar to those described in section 4 (below).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Teriflunomide Desitin
Do not take a double dose to make up for forgotten doses. Take your next dose at the usual time.
If you stop taking Teriflunomide Desitin
Do not stop treatment or change the dose of teriflunomide without consulting your doctor first.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
The following side effects may occur with this medication.
Serious side effects
Some side effects may be serious, and if you experience any of them, inform your doctor immediately.
Frequent(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Frequency not known(frequency cannot be estimated from the available data):
Other side effectsmay occur with the following frequencies:
Very common(may affect more than 1 in 10 people)
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 patients)
Frequency not known(frequency cannot be estimated from the available data)
Children (10 years of age and older) and adolescents
The side effects listed above also apply to children and adolescents. The following additional information is important for children, adolescents, and their caregivers:
Frequent(may affect up to 1 in 10 people)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack after "EXP". The expiration date is the last day of the indicated month.
This medication does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Teriflunomida Desitin
Tablet core: lactose monohydrate, corn starch, hydroxypropylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose (type A), anhydrous colloidal silica, magnesium stearate.
Coating material: hypromellose, titanium dioxide (E171), talc, macrogol 6000, indigo carmine (E132).
Appearance of the Product and Package Contents
The film-coated tablets are blue, pentagonal in shape, approximately 7.30 x 7.20 mm, engraved with "T2" on one side and smooth on the other side.
Teriflunomida Desitin 14 mg film-coated tablets are available in cardboard boxes containing 14, 28, and 84 film-coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder
Desitin Arzneimittel GmbH
Weg Beim Jaeger 214
22335 - Hamburg –
Germany
Manufacturer
Laboratori Fundació Dau
Calle C, 12-14 Pol. Industrial Zona Franca
08040 – Barcelona
Spain
This medication is authorized in the member states of the European Economic Area under the following names:
Germany Teriflunomid Eignapharma 14 mg Filmtabletten
France Teriflunomide Eignapharma 14 mg, comprimé pelliculé
Czech Republic Teriflunomid Desitin
Denmark Teriflunomid Desitin
Spain Teriflunomida Desitin 14 mg film-coated tablets EFG
Finland Teriflunomide Desitin 14 mg kalvopäällysteiset tabletit
Norway Teriflunomide Desitin
Romania Teriflunomida Desitin 14 mg comprimate filmate
Sweden Teriflunomide Desitin
Slovakia Teriflunomide Desitin 14 mg filmom obalené tablety
Date of the Last Revision of this Leaflet:
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/